[
    [
        {
            "time": "2018-01-02",
            "original_text": "Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio",
            "features": {
                "keywords": [
                    "New Year",
                    "Adding",
                    "Stocks",
                    "Portfolio"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Yahoo Finance Presents: Senator Kirsten Gillibrand",
            "features": {
                "keywords": [
                    "Yahoo Finance",
                    "Senator",
                    "Kirsten Gillibrand"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Yahoo Finance Presents: Senator Kirsten Gillibrand",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia",
            "features": {
                "keywords": [
                    "Bristol Myers",
                    "FDA",
                    "Nod",
                    "MS Drug",
                    "Zeposia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Drugmaker Vertex to delay new clinical studies due to coronavirus",
            "features": {
                "keywords": [
                    "Drugmaker",
                    "Vertex",
                    "delay",
                    "clinical studies",
                    "coronavirus"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Drugmaker Vertex to delay new clinical studies due to coronavirus",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]